Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept

NCT04707027 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Polypoidal Choroidal Vasculopathy

Interventions

DRUG: Aflibercept Injection (2 mg/0.05 ml)
OTHER: Defer treatment

Sponsor

Chiang Mai University